Within our prostate cancer portfolio, PNT2002 is our investigational PSMA targeted radiotherapeutic for the treatment of patients with metastatic castrate-resistant prostate cancer. We recently ...

预计CMS的监管更新将改善患者获得专业诊断放射性药物（包括PYLARIFY）的机会。 公司的产品管线正在推进，其中用于阿尔茨海默病的MK-6240和NAV-4694以及用于前列腺癌的PNT2002显示出前景。 Lantheus拥有8.664亿美元的现金和等价物，流动性状况良好。 公司展望 全年 ...

The Company plans to submit New Drug Applications for MK-6240 in 2025 and NAV-4694 in 2026. With respect to the SPLASH Phase 3 registrational study of PNT2002, the second interim analysis performed at ...

With respect to the SPLASH Phase 3 registrational study of PNT2002, the second interim analysis performed at 75% of protocol specified events demonstrated results for radiographic progression free ...

This webpage is supported through an unrestricted educational grant from Bayer. Bayer is not involved in content development and the views expressed represent those of the patient and physician ...

This structure only posts the bid and ask quotes for specific stocks dealers are willing to trade. In a purely quote-driven market structure, traders must interact directly with dealers ...

As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ramped up legal actions against its competitors. In a series of lawsuits filed this year, Novartis has alleged that ...

In a report released today, Matthew Taylor from Jefferies maintained a Buy rating on Lantheus (LNTH – Research Report), with a price target of $145.00. The company’s shares closed last Friday ...